Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial of Corfluvec Intranasal Vector Vaccine for the Prevention of COVID-19 in Healthy Volunteers Aged 18 to 60 Years

NCT05696067 is registered in ClinicalTrials.gov with Tatyana Zubkova as lead sponsor.

NCT NCT05696067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled Phase 1/2 Trial of Corfluvec Intranasal Vector Vaccine for the Prevention of COVID-19 in Healthy Volunteers Aged 18 to 60 Years
Lead sponsor
Tatyana Zubkova
Phase
Phase 1/2
Overall status
Completed
Start date
September 13, 2022
Completion date
May 31, 2023
Enrollment
200 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19